NM.C

Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Why some stocks are undervalued A lot of things go into determining a company’s share price, but in a young emerging industry like psychedelics, many of the traditional measurements…
Novamind (NM.C) announced that they have opened a new Novamind Client Care Center to manage the “overwhelming demand for its treatments”. The new client care center is located in…
Survivors of childhood trauma Everyone’s therapy journey is different. Some people can move past what they are dealing with purely through talk therapy.  By understanding on a logical level…
Novamind (NM.C) announced they are opening four new Cedar Psychiatric clinics, doubling the number of clinics in there network. The expanded capacity for the new clinics is intended to…
Novamind (NM.C) shared the preliminary findings from two studies which involved using Ketamine-Assisted Psychotherapy (KAP) to treat eating disorders. The studies were done in collaboration with Center for Change….
$13 million give or take Earlier this week the law firms of Wolf Haldenstein Adler Freeman & Herz and The Portnoy Law Firm both announced class-action lawsuits against psychedelics…
Cedar Clinical Research Novamind (NM.C) announced today it’s increasing its investment in the Australian-based drug company Bionomics (BNO.ASX). The company is focused primarily on anxiety, PTSD, and central nervous…
Novamind (NM.C) announced that their wholly-owned subsidiary, Cedar Clinical Research (CCR), has been selected by Merck to be a key research site for a clinical trial focused on treatment-resistant…